Stay updated on Atrasentan in IgA Nephropathy Clinical Trial
Sign up to get notified when there's something new on the Atrasentan in IgA Nephropathy Clinical Trial page.

Latest updates to the Atrasentan in IgA Nephropathy Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedAdded the final Lancet publication citation for the ALIGN IgA nephropathy results and removed the earlier online-ahead-of-print Lancet citation, updating the Publications section to reflect the final article.SummaryDifference0.0%

- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedA new publication citation by Kuo et al. on atrasentan and IgA nephropathy is added to Publications. The page revision is updated to v3.6.3, reflecting updated scholarly references and versioning for the ALIGN study.SummaryDifference0.0%

- Check42 days agoChange DetectedAdds a recruitment status note indicating the trial is no longer recruiting participants and includes new navigation items such as 'How to Read a Study Record', 'Common Questions', and 'How to Join a Study'; removes the old 'Intervention / Treatment' label in favor of 'Intervention/Treatment' and adds the site revision note 'Revision: v3.6.0'.SummaryDifference0.2%

- Check49 days agoChange DetectedNovartis Pharmaceuticals is now listed as sponsor with new identifiers and drug details added. The study plan now includes an open-label atrasentan extension, a zigakibart substudy, and updated timelines including primary completion in 2028-04-14 and enrollment of 404 participants.SummaryDifference2%

- Check56 days agoChange DetectedA new publication citation was added under Publications. It lists the Kidney360 article on atrasentan in IgA nephropathy (online ahead of print, 2025).SummaryDifference0.0%

- Check70 days agoChange DetectedThe page’s revision tag was updated from v3.5.3 to v3.5.4, indicating a new release of the site framework or content management. This change reflects an internal version update rather than an alteration to the study information or visible user content.SummaryDifference0.0%

Stay in the know with updates to Atrasentan in IgA Nephropathy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Atrasentan in IgA Nephropathy Clinical Trial page.